Navigator Medicines, Inc.
Navigator Medicines is a clinical-stage biopharmaceutical company focused on discovering pathways and partnerships to advance treatments for autoimmune diseases. They leverage next-generation biologics targeting mechanisms like OX40L and TNFα to develop therapies for difficult-to-treat autoimmune conditions, aiming to improve patient outcomes with safe and effective treatments.
Industries
Nr. of Employees
small (1-50)
Navigator Medicines, Inc.
2525 Smith Street, Scotch Plains, NJ 07076
Products
Clinical-stage bispecific antibody targeting OX40L and TNFα (clinical)
A tetravalent bispecific antibody designed to block both OX40L- and TNFα-mediated signaling to downregulate inflammation; advanced into Phase 1 clinical evaluation for autoimmune indications.
Second-generation OX40L x TNFα bispecific (preclinical)
A next-generation bispecific antibody program intended to improve on earlier multispecific constructs, currently in preclinical development.
OX40L-targeted monoclonal antibody (preclinical)
A monoclonal antibody program directed at OX40L, in preclinical development for autoimmune indications.
Discovery-stage OX40L-based multispecific programs
Early discovery programs exploring OX40L-targeted multispecific antibody constructs and combinations with additional mechanisms.
Clinical-stage bispecific antibody targeting OX40L and TNFα (clinical)
A tetravalent bispecific antibody designed to block both OX40L- and TNFα-mediated signaling to downregulate inflammation; advanced into Phase 1 clinical evaluation for autoimmune indications.
Second-generation OX40L x TNFα bispecific (preclinical)
A next-generation bispecific antibody program intended to improve on earlier multispecific constructs, currently in preclinical development.
OX40L-targeted monoclonal antibody (preclinical)
A monoclonal antibody program directed at OX40L, in preclinical development for autoimmune indications.
Discovery-stage OX40L-based multispecific programs
Early discovery programs exploring OX40L-targeted multispecific antibody constructs and combinations with additional mechanisms.
Services
Sponsor-led design and conduct of early-phase clinical trials including first-in-human SAD studies and Phase 1b dosing for investigational biologics.
Structuring and managing in-licensing agreements and strategic collaborations to acquire or co-develop biologic programs.
Sponsor-led design and conduct of early-phase clinical trials including first-in-human SAD studies and Phase 1b dosing for investigational biologics.
Structuring and managing in-licensing agreements and strategic collaborations to acquire or co-develop biologic programs.
Expertise Areas
- Clinical trial management (first-in-human SAD and Phase 1b)
- Antibody engineering and multispecific biologics
- Translational immunology focused on OX40L and TNFα pathways
- Preclinical to clinical translational development
Key Technologies
- Bispecific antibody engineering
- Monoclonal antibody development
- Tetravalent antibody constructs
- Immunomodulatory targeting of OX40L
News & Updates
Navigator Medicines announced the dosing of first participants in a Phase 1b trial of NAV-240, a bispecific antibody targeting OX40L and TNFα for autoimmune diseases.
Navigator Medicines announced the dosing of first participants in a Phase 1b trial of NAV-240, a bispecific antibody targeting OX40L and TNFα for autoimmune diseases.